We observed a statistically signifi -
cant 29% reduction in the relative risk of advanced lesions for
higher-dose aspirin vs placebo. In the two trials that evaluated lower
doses of aspirin (doses of ≤ 160 mg/d) vs placebo, there was a statistically
signifi cant 17% decrease in the relative risk of any adenoma
(absolute risk reduction = 8.4%) and a non – statistically signifi cant
17% reduction in the relative risk of advanced lesions